SO
55
-2
MCO
73
3
EW
37
-2
STI
47
-12
FDX
36
-4
QCOM
48
-7
URI
53
-2
KMX
58
3
EXC
54
-2
FRT
39
-2
BIIB
26
2
PCG
93
2
EQT
59
2
PPL
54
2
IBM
54
4
PDCO
35
-3
LLY
39
9
COST
58
-2
AMGN
44
5
A
36
2
SO
55
-2
MCO
73
3
EW
37
-2
STI
47
-12
FDX
36
-4
QCOM
48
-7
URI
53
-2
KMX
58
3
EXC
54
-2
FRT
39
-2
BIIB
26
2
PCG
93
2
EQT
59
2
PPL
54
2
IBM
54
4
PDCO
35
-3
LLY
39
9
COST
58
-2
AMGN
44
5
A
36
2
Financhill
Back

Nektar Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
30

NKTR
Nektar Therapeutics

Last Price:
1.02
Seasonality Move:
15.74%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Nektar Therapeutics Price Quote

$1.02
+0.02 (+2%)
(Updated: November 21, 2024 at 5:55 PM ET)

Nektar Therapeutics Key Stats

Sell
30
Nektar Therapeutics (NKTR) is a Sell
Day range:
$1.00 - $1.07
52-week range:
$0.42 - $1.93
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.22
P/B ratio:
3.89%
Volume:
1.5M
Avg. volume:
1.7M
1-year change:
92.31%
Market cap:
$190M
Revenue:
$90.1M
EPS:
$-0.84

How Much Does Nektar Therapeutics Make?

Is Nektar Therapeutics Growing As A Company?

  • What Is Nektar Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0%
  • What Is Nektar Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Nektar Therapeutics Stock Price Performance

What Is Nektar Therapeutics 52-Week High & Low?

Nektar Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Nektar Therapeutics?

Is Nektar Therapeutics Cash Flow Positive?

  • What Is NKTR Cash Flow From Operations?
    Cash flow from operations (TTM) is -$176.6M
  • What Is Nektar Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $42M
  • What Is Nektar Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $99.7M

Nektar Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    NKTR return on invested capital is -154.23%
  • What Is Nektar Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -44.58%
  • What Is NKTR Return On Equity?
    ROE is a measure of profitability and is -154.23%

Nektar Therapeutics Earnings Date & Stock Price

Nektar Therapeutics Competitors

  • Who Are Nektar Therapeutics's Competitors?
    Below is a list of companies who compete with Nektar Therapeutics or are related in some way:
    • Esperion Therapeutics Inc (ESPR)
    • iBio Inc (IBIO)
    • Eli Lilly and Co (LLY)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Nektar Therapeutics Dividend Yield

Nektar Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 14.26%
Revenue: -0.08% 31.97%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 4.10
Upside from Last Price: 310%

Major Shareholders

  • How many NKTR shares are owned by institutional investors?
    168.4M NKTR shares are owned by institutional investors
  • How many NKTR shares are owned by insiders?
    4.8M NKTR shares are owned by insiders